Abstract
Evidence on the cost and cost-effectiveness of treatment of multidrug-resistant tuberculosis (MDR-TB) is limited, and no published data are available from former Soviet Union countries, where rates of MDR-TB are highest globally. We evaluated the cost and cost-effectiveness of MDR-TB treatment in Estonia and Russia (Tomsk Oblast), comparing cohorts enrolled on treatment according to World Health Organization (WHO) guidelines in 2001 and 2002 with cohorts treated in previous years. Costs were assessed from a health system perspective in 2003 US$; effects were measured as cures, deaths averted and disability-adjusted life-years (DALYs) averted. Cure rates when WHO guidelines were followed were 61% (90 out of 149) in Estonia and 76% (76 out of 100) in Tomsk Oblast, with a cost per patient treated of US$8,974 and US$10,088, respectively. Before WHO guidelines were followed, cure rates were 52% in Estonia and 15% in Tomsk Oblast; the cost per patient treated was US$4,729 and US$2,282, respectively. Drugs and hospitalisation accounted for 69-90% of total costs. The cost per DALY averted by treatment following WHO guidelines was US$579 (range US$297-US$902) in Estonia and US$429 (range US$302-US$546) in Tomsk Oblast. Treatment of pati...Continue Reading
Citations
Apr 2, 2013·Lancet·Johan P MackenbachMartin McKee
Mar 5, 2013·PloS One·Chunling LuCarole D Mitnick
Sep 9, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y HuB Xu
May 6, 2015·PharmacoEconomics·Yoko V LaurenceAnna Vassall
Mar 27, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Masoud DaraGiovanni Battista Migliori
Mar 27, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Giovanni SotgiuGiovanni Battista Migliori
Feb 7, 2015·PloS One·Juliet N SekandiPhaedra S Corso
Dec 3, 2014·PLoS Medicine·Chunling LuFidele Ngabo
Oct 22, 2016·Clinical Drug Investigation·Ji-Hye ByunEui-Kyung Lee
Dec 16, 2016·Drug Development and Industrial Pharmacy·Stefano GiovagnoliMaurizio Ricci
Jan 13, 2017·AIDS·UNKNOWN TB:HIV Study writing Group
Apr 19, 2018·PloS One·Marian LovedayEmmanuelle Daviaud
Jan 30, 2019·PloS One·E N BogdanovaE Gospodarevskaya
Sep 28, 2014·The European Respiratory Journal·Dennis FalzonMario Raviglione
Sep 3, 2016·The European Respiratory Journal·Carole D MitnickUNKNOWN Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment
Jan 2, 2015·The European Respiratory Journal·Karapet DavtyanGiovanni Battista Migliori
Jan 1, 2015·International Journal of Technology Assessment in Health Care·Olena MandrikJohan L Severens
Nov 10, 2015·Bulletin of the World Health Organization·Christopher FitzpatrickKatherine Floyd
Jul 20, 2020·Infectious Diseases of Poverty·Xu-Bin ZhengBiao Xu
Oct 18, 2020·International Journal of Environmental Research and Public Health·Aizhamal TabyshovaJob F M van Boven
Dec 2, 2020·PloS One·Florence O BadaAlash'le Abimiku